MIR526A2: A Potential Drug Target and Biomarker (G574486)

Target Name: MIR526A2

NCBI ID: G574486

MIR526A2

MIR526A2: A Potential Drug Target and Biomarker

MIR526A2, a protein encoded by the MIRN526A gene, is a potential drug target and biomarker that has been identified for its role in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and expression pattern have made it an attractive target for researchers to investigate, and its potential as a drug have piqued the interest of pharmaceutical companies.

MIR526A2 is a 21-kDa transmembrane protein that is expressed in various tissues and organs, including brain, spinal cord, pancreas, and peripheral tissues. It is characterized by a N-terminal cytoplasmic domain, a unique G-quadruplex loop in the middle of the protein, and a C-terminal T-spike. The N-terminal domain contains a putative G protein-coupled receptor (GPCR) domain, which is known for its role in signaling pathways. The GPCR domain is responsible for the binding of the drug to the protein, allowing MIR526A2 to act as a drug target.

MIR526A2 has been shown to play a role in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, MIR526A2 has been shown to be overexpressed in various types of cancer, including breast, lung, and ovarian cancer. It has also been linked to neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases, as well as autoimmune disorders, such as multiple sclerosis and rheumatoid arthritis.

One of the challenges in studying MIR526A2 is its expression pattern. MIR526A2 is expressed in various tissues and organs, including brain, spinal cord, pancreas, and peripheral tissues. Its expression pattern is highly variable, and its levels can vary depending on the tissue and disease state. This makes it difficult to study its function and potential as a drug target.

In addition, the structure of MIR526A2 is also of interest. The N-terminal domain of MIR526A2 contains a GPCR domain, which is known for its role in signaling pathways. The GPCR domain is responsible for the binding of the drug to the protein, allowing MIR526A2 to act as a drug target. The C-terminal T-spike is also of interest, as it may be involved in the regulation of MIR526A2 function.

To study the function of MIR526A2, researchers have used various techniques, including RNA interference, overexpression, and biochemical assays. For example, researchers have used RNA interference to knock down the expression of MIR526A2 in cancer cells and mouse models of cancer. They have also used overexpression to increase the expression of MIR526A2 in cancer cells and mouse models of cancer.

In addition, researchers have also used biochemical assays to study the function of MIR526A2. They have used Immunofluorescence to visualize the expression of MIR526A2 in various tissues and organs, including cancer cells and mouse models of cancer. They have also used Western blotting to measure the levels of MIR526A2 in various tissues and organs.

Despite the efforts made to study MIR526A2, its potential as a drug target is still uncertain. Further research is needed to understand its function and its potential as a drug. One way to do this is through the use of knockout MIR

Protein Name: MicroRNA 526a-2

The "MIR526A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR526A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets